Currently, OPN belongs to phase III biomarkers, which has accuracy and diagnostic value comparable to AFP in the diagnosis of HCC at a cut-off value of 280 ng/mL [123,124]. This evidence concerns the gene AFP and hepatocellular carcinoma.